Literature DB >> 28628333

Coupling Targeted and Untargeted Mass Spectrometry for Metabolome-Microbiome-Wide Association Studies of Human Fecal Samples.

Alexey V Melnik1, Ricardo R da Silva1, Embriette R Hyde2, Alexander A Aksenov1, Fernando Vargas1, Amina Bouslimani1, Ivan Protsyuk3, Alan K Jarmusch1, Anupriya Tripathi1,2,4, Theodore Alexandrov1,3, Rob Knight2,5, Pieter C Dorrestein1.   

Abstract

Increasing appreciation of the gut microbiome's role in health motivates understanding the molecular composition of human feces. To analyze such complex samples, we developed a platform coupling targeted and untargeted metabolomics. The approach is facilitated through split flow from one UPLC, joint timing triggered by contact closure relays, and a script to retrieve the data. It is designed to detect specific metabolites of interest with high sensitivity, allows for correction of targeted information, enables better quantitation thus providing an advanced analytical tool for exploratory studies. Procrustes analysis revealed that untargeted approach provides a better correlation to microbiome data, associating specific metabolites with microbes that produce or process them. With the subset of over one hundred human fecal samples from the American Gut project, the implementation of the described coupled workflow revealed that targeted analysis using combination of single transition per compound with retention time misidentifies 30% of the targeted data and could lead to incorrect interpretations. At the same time, the targeted analysis extends detection limits and dynamic range, depending on the compounds, by orders of magnitude. A software application has been developed as a part of the workflow to allows for quantitative assessments based on calibration curves. Using this approach, we detect expected microbially modified molecules such as secondary bile acids and unexpected microbial molecules including Pseudomonas-associated quinolones and rhamnolipids in feces, setting the stage for metabolome-microbiome-wide association studies (MMWAS).

Entities:  

Mesh:

Year:  2017        PMID: 28628333     DOI: 10.1021/acs.analchem.7b01381

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  26 in total

Review 1.  Gut microbiota-derived metabolites as key actors in inflammatory bowel disease.

Authors:  Aonghus Lavelle; Harry Sokol
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-02-19       Impact factor: 46.802

2.  A strategy combining solid-phase extraction, multiple mass defect filtering and molecular networking for rapid structural classification and annotation of natural products: characterization of chemical diversity in Citrus aurantium as a case study.

Authors:  Yi-Kun Wang; Xue-Rong Xiao; Zi-Meng Zhou; Yao Xiao; Wei-Feng Zhu; Hong-Ning Liu; Fei Li
Journal:  Anal Bioanal Chem       Date:  2021-04-06       Impact factor: 4.142

Review 3.  Finding intestinal fortitude: Integrating the microbiome into a holistic view of depression mechanisms, treatment, and resilience.

Authors:  M C Flux; Christopher A Lowry
Journal:  Neurobiol Dis       Date:  2019-08-24       Impact factor: 5.996

4.  Dual mass spectrometry as a tool to improve annotation and quantification in targeted plasma lipidomics.

Authors:  Liang Gao; Amaury Cazenave-Gassiot; Bo Burla; Markus R Wenk; Federico Torta
Journal:  Metabolomics       Date:  2020-04-17       Impact factor: 4.290

Review 5.  Moving beyond descriptive studies: harnessing metabolomics to elucidate the molecular mechanisms underpinning host-microbiome phenotypes.

Authors:  Stephanie L Bishop; Marija Drikic; Soren Wacker; Yuan Yao Chen; Anita L Kozyrskyj; Ian A Lewis
Journal:  Mucosal Immunol       Date:  2022-08-15       Impact factor: 8.701

Review 6.  Mass spectrometry-based metabolomics in microbiome investigations.

Authors:  Anelize Bauermeister; Helena Mannochio-Russo; Letícia V Costa-Lotufo; Alan K Jarmusch; Pieter C Dorrestein
Journal:  Nat Rev Microbiol       Date:  2021-09-22       Impact factor: 78.297

Review 7.  Microbiome 101: Studying, Analyzing, and Interpreting Gut Microbiome Data for Clinicians.

Authors:  Celeste Allaband; Daniel McDonald; Yoshiki Vázquez-Baeza; Jeremiah J Minich; Anupriya Tripathi; David A Brenner; Rohit Loomba; Larry Smarr; William J Sandborn; Bernd Schnabl; Pieter Dorrestein; Amir Zarrinpar; Rob Knight
Journal:  Clin Gastroenterol Hepatol       Date:  2018-09-18       Impact factor: 11.382

8.  XCMS-MRM and METLIN-MRM: a cloud library and public resource for targeted analysis of small molecules.

Authors:  Xavier Domingo-Almenara; J Rafael Montenegro-Burke; Julijana Ivanisevic; Aurelien Thomas; Jonathan Sidibé; Tony Teav; Carlos Guijas; Aries E Aisporna; Duane Rinehart; Linh Hoang; Anders Nordström; María Gómez-Romero; Luke Whiley; Matthew R Lewis; Jeremy K Nicholson; H Paul Benton; Gary Siuzdak
Journal:  Nat Methods       Date:  2018-08-27       Impact factor: 28.547

9.  Pivotal Dominant Bacteria Ratio and Metabolites Related to Healthy Body Index Revealed by Intestinal Microbiome and Metabolomics.

Authors:  Lingyun Zou
Journal:  Indian J Microbiol       Date:  2021-11-09       Impact factor: 2.461

10.  Human Gut Microbiota from Autism Spectrum Disorder Promote Behavioral Symptoms in Mice.

Authors:  Gil Sharon; Nikki Jamie Cruz; Dae-Wook Kang; Michael J Gandal; Bo Wang; Young-Mo Kim; Erika M Zink; Cameron P Casey; Bryn C Taylor; Christianne J Lane; Lisa M Bramer; Nancy G Isern; David W Hoyt; Cecilia Noecker; Michael J Sweredoski; Annie Moradian; Elhanan Borenstein; Janet K Jansson; Rob Knight; Thomas O Metz; Carlos Lois; Daniel H Geschwind; Rosa Krajmalnik-Brown; Sarkis K Mazmanian
Journal:  Cell       Date:  2019-05-30       Impact factor: 66.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.